Phio Pharmaceuticals's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Phio Pharmaceuticals in the second quarter 2026?
Phio Pharmaceuticals Corp recorded a cumulative net loss of $-13 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -87.41%.

Within the Major Pharmaceutical Preparations industry 241 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 3444, from total ROE ranking in the first quarter 2026 at 3949.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	24.83 %	35.27 %	326.57 %	98.93 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-13	-11	-9	-8	-7
Return On Equity (TTM)	-87.41 %	-77.34 %	-66.59 %	-86.38 %	-88.75 %
PHIO's Total Ranking	# 3444	# 3949	# 3541	# 3593	# 3719
Equity (TTM) in Millions	13	16	20	10	10
Seq. Equity Change	-23.45 %	-18.29 %	104.77 %	-2.54 %	-17.05 %
Seq. Net Income Change	-	-	-	-	-

Back to PHIO Management Effectiveness >> PHIO's 5 Years Annual ROE >> Compare PHIO ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 242
Sector	# 530
Overall	# 3444

Return On Equity Statistics
High	Average	Low
-48.99 %	-192.68 %	-2617.67 %
(Jun 30 2021)		(Jun 30 2013)

News about Phio Pharmaceuticals Corp Return on Equity ROE

The Under-Performance of Phio Pharmaceuticals Corp Shares A Review and Analysis

:This article explores the recent under-performance of Phio Pharmaceuticals Corp shares and provides an analysis of the factors contributing to this trend. The study examines the impact of various events, including the exercise of warrants, termination of a share purchase agreement, and the company s financial performance. It also compares Phio Pharmaceuticals Corp s return on equity (ROE) with its peers in the Major Pharmaceutical Preparations industry. The article concludes with insights into the company s current position in the market and potential future prospects.Phio Pharmaceuticals Corp, a clinical-stage biotechnology company, has experienced a decline in the performance of its shares in recent weeks. This article aims to investigate the underlying reasons for this under-performance and shed light on the potential implications for investors and the company itself.

PHIO Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	20	5	8	11	22
Y / Y Equity Change	326.57 %	-38.9 %	-28.68 %	-50.58 %	68.49 %
Net Income in Millions	-9	-7	-11	-11	-13
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-43.17 %	-151.39 %	-140.05 %	-105.92 %	-60.58 %

Back to PHIO Management Effectiveness >> PHIO's 5 Years Annual ROE >> Compare PHIO ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PHIO's' Return on Equity at Yahoo Finance
PHIO's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PHIO's Competitors
Subscribers only: Roe for Phio Pharmaceuticals's Suppliers
Subscribers only: Return On Equity for PHIO's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector

ROE

Date modified: 2026-09-08T20:02:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.